Medication adherence and costs of medical care among patients with Parkinson’s disease: an observational study using electronic medical records

Zhanmiao Yi,Yudan Mao,Chenxuan He,Yantao Zhang,Junwen Zhou,Xing Lin Feng

DOI: https://doi.org/10.1186/s12889-024-18431-y

IF: 4.5

2024-04-30

BMC Public Health

Abstract:Abstract Background Adherence to antiparkinsonian drugs (APDs) is critical for patients with Parkinson’s disease (PD), for which medication is the main therapeutic strategy. Previous studies have focused on specific disorders in a single system when assessing clinical factors affecting adherence to PD treatment, and no international comparative data are available on the medical costs for Chinese patients with PD. The present study aimed to evaluate medication adherence and its associated factors among Chinese patients with PD using a systematic approach and to explore the impact of adequate medication adherence on direct medical costs. Methods A retrospective analysis was conducted using the electronic medical records of patients with PD from a medical center in China. Patients with a minimum of two APD prescriptions from January 1, 2016 to August 15, 2018 were included. Medication possession ratio (MPR) and proportion of days covered were used to measure APD adherence. Multiple linear regression analysis was used to identify factors affecting APD adherence. Gamma regression analysis was used to explore the impact of APD adherence on direct medical costs. Results In total, 1,712 patients were included in the study, and the mean MPR was 0.68 (± 0.25). Increased number of APDs and all medications, and higher daily levodopa-equivalent doses resulted in higher MPR (mean difference [MD] = 0.04 [0.03–0.05]; MD = 0.02 [0.01–0.03]; MD = 0.03 [0.01–0.04], respectively); combined digestive system diseases, epilepsy, or older age resulted in lower MPR (MD = -0.06 [-0.09 to -0.03]; MD = -0.07 [-0.14 to -0.01]; MD = -0.02 [-0.03 to -0.01], respectively). Higher APD adherence resulted in higher direct medical costs, including APD and other outpatient costs. For a 0.3 increase in MPR, the two costs increased by $34.42 ($25.43–$43.41) and $14.63 ($4.86–$24.39) per year, respectively. Conclusions APD adherence rate among Chinese patients with PD was moderate and related primarily to age, comorbidities, and healthcare costs. The factors should be considered when prescribing APDs.

public, environmental & occupational health

What problem does this paper attempt to address?

This paper aims to address issues related to the compliance of anti - Parkinson's drugs (APDs) and direct medical costs among Parkinson's disease (PD) patients in China. Specifically, the research objectives include:

1. **Evaluating drug compliance**: Systematically evaluate the APD compliance of PD patients in China and its related factors. The study uses the Medication Possession Ratio (MPR) and the Proportion of Days Covered (PDC) to measure APD compliance.

2. **Exploring the impact of compliance on medical costs**: The study also explores the impact of good APD compliance on direct medical costs, especially drug costs and other outpatient costs.

### Research Background
- Parkinson's disease is the second most common neurodegenerative disease globally, mainly affecting adults aged 65 and above.
- With the aging of the population, the disease burden of PD has increased significantly.
- Drug treatment is the main treatment strategy for PD, but poor drug compliance will reduce the patient's quality of life and increase the risk of complications and death.
- Previous studies have mainly focused on clinical factors of specific diseases or single systems, lacking international comparison data, especially in terms of medical costs for PD patients in China.

### Research Methods
- **Data sources**: The study used electronic medical record data from a tertiary hospital in China from January 1, 2016 to August 15, 2018.
- **Sample selection**: PD patients with at least two APD prescriptions were included.
- **Compliance indicators**: MPR and PDC were used to measure APD compliance.
- **Statistical analysis**: Multiple linear regression analysis and Gamma regression analysis were used to identify factors affecting APD compliance and their impact on medical costs.

### Main Results
- **Compliance situation**: The average MPR of 1,712 patients was 0.68 (standard deviation 0.25), and the compliance was divided into low, medium, and high groups.
- **Influencing factors**:
- Older patients, or those with digestive system diseases or epilepsy, had lower MPR.
- Using more APDs or other drugs, and a higher daily levodopa - equivalent dose (LED), led to a higher MPR.
- **Medical costs**:
- Higher APD compliance was associated with higher direct medical costs, especially drug costs and other outpatient costs.
- For every 0.3 increase in MPR, APD costs increased by $34.42 per year (95% CI: $25.43 - $43.41), and other outpatient costs increased by $14.63 per year (95% CI: $4.86 - $24.39).

### Conclusions
- The APD compliance of PD patients in China is moderate, mainly related to age, comorbidities, and medical costs.
- Good APD compliance can improve symptoms and quality of life, but it will also increase direct medical costs.
- The healthcare system should consider these factors to improve drug compliance in PD patients.

### Formula Display
- **MPR calculation formula**:
\[
\text{MPR}=\frac{\sum (\text{prescription days})}{\text{observation period days}}
\]
- **PDC calculation formula**:
\[
\text{PDC}=\frac{\sum (\text{days with drug coverage})}{\text{observation period days}}
\]

Through these formulas, the study can accurately measure patients' drug compliance and further analyze its impact on medical costs.